FUCIDIN FILM COATED TAB 250MG TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

FUSIDATE SODIUM

Prieinama:

LEO PHARMA INC

ATC kodas:

J01XC01

INN (Tarptautinis Pavadinimas):

FUSIDIC ACID

Dozė:

250MG

Vaisto forma:

TABLET

Sudėtis:

FUSIDATE SODIUM 250MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

100

Recepto tipas:

Prescription

Gydymo sritis:

OTHER MISCELLANEOUS ANTIBACTERIAL AGENTS*

Produkto santrauka:

Active ingredient group (AIG) number: 0114229002; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2009-06-05

Prekės savybės

PRODUCT MONOGRAPH
PR
FUCIDIN®
Sodium fusidate
Film Coated Tablets, 250 mg
Antibiotic
LEO Pharma Inc.
Thornhill, Ontario
L3T 7W8
www.leo-pharma.com/canada
Date of Revision:
FEBRUARY 16, 2010
Submission Control No: 134282
®Registered trademark of LEO Pharma A/S used under license by LEO
Pharma Inc., Thornhill, ON
LEO®
_ _
_FUCIDIN® (sodium fusidate) Product Monograph, version 2.0_
_Page 2_
_ of _
_30_
NAME OF DRUG
PR
FUCIDIN®
Sodium fusidate
Film Coated Tablets, 250 mg
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
The antibacterial action of fusidic acid results from the inhibition
of bacterial protein synthesis.
The drug interferes with amino acid transfer from aminoacyl-tRNA to
proteins undergoing
biosynthetic process on the ribosomes. Although bacterial cells stop
dividing almost within two
minutes after contact with the antibiotic in vitro, DNA and RNA
synthesis continue for 45
minutes and 1-2 hours, respectively.
(13,37,38,45)
CLINICAL PHARMACOLOGY
Fusidic
acid
is
active
against
a
wide
range
of
gram
positive
organisms,
particularly
staphylococci.
(2,10)
Other species against which fusidic acid exerts high clinical activity
include
Streptococci, (including Pneumococci) and Corynebacteria.
(2,10,14)
Fusidic acid is virtually inactive against most gram negative
bacteria. The differences in activity
against gram negative and gram positive organisms are believed to be
due to a difference in cell
LEO®
_ _
_FUCIDIN® (sodium fusidate) Product Monograph, version 2.0_
_Page 3_
_ of _
_30_
wall permeability.
Mammalian cells are much less susceptible to inhibition of protein
synthesis by FUCIDIN
(fusidic acid) than sensitive bacterial cells. These differences are
believed to be due primarily to a
difference in cell wall permeability.
No cross-resistance has been observed to date between FUCIDIN and
other antibiotics presently
in clinical use.
CLINICAL PHARMACOKINETICS
FUCIDIN (fusidic acid) has a somewhat steroid like structure but does
not exhibit any steroid
like pharmacological activity (ie. hormonal or anti-infl